Here are the DEF 14A proxy statements from Insulet Corporation (PODD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow PODD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PODD filings page.
Insulet Corporation reports strong 2025 growth and seeks shareholder approvals at its 2026 virtual annual meeting. Revenue reached about $2.7 billion with roughly 31% growth, gross margin was 71.6%, operating margin 17.5%, and free cash flow about $375 million, reflecting a highly profitable, recurring-revenue model.
The company highlights 10 consecutive years of at least 20% constant currency revenue growth, driven by Omnipod 5 adoption, global expansion and rising Type 2 diabetes use. The proxy asks shareholders to elect three Class I directors, approve executive pay on an advisory basis, and ratify the independent auditor. Insulet emphasizes a largely independent board, performance‑heavy executive compensation, formal clawback and stock ownership guidelines, and growing sustainability initiatives, including global Pod recycling and expanded renewable energy use.